Differential Regulation of HOXA10 Gene in Ovarian Cancer and Endometriosis by ERα/β

• Main Authors: Yu-Fang Lin, 林昱妦
• Other Authors: Nancy M. Wang
• Format: Others
• Language: en_US
• Published: 2009
• Online Access: http://ndltd.ncl.edu.tw/handle/92572384300061765728

碩士 === 國立彰化師範大學 === 生物技術研究所 === 97 === HOXA10 is a member of the homeobox genes family which they are transcription factors. HOXA10 is expressed in development of female reproductive tract and participates in the endometrial differentiation and may contribute to development of endometriosis and epithelial ovarian cancer (EOC). The purpose of the study is to detect and compare HOXA10 expression in the tissues of endometriosis and ovarian cancer in order to understand its role in differential regulation in these two gynaecological diseases under hormonal control. Expressions of HOXA10, ESR1 (ERα), ESR2 (ERβ) and PGR (PR) gene were quantitated in 140 patients with endometriosis and 19 women without endometriosis, and 79 ovarian cancerous tissues were determined by real-time PCR. Our data showed that expression of HOXA10, ESR1 and ESR2 were 1.60 to 2.41 folds higher and PGR was 2.80 folds lower in EOC than normal tissues. However, in endometriosis HOXA10, ESR1 and PGR were 20.1, 1.67 and 3.04 folds lower, respectively, and ESR2 was higher expression by 4.52 folds. The higher expression of HOXA10 in EOC and lower in endometriosis were coincidence with ESR1, which may support that higher expression of ESR1 manages HOXA10 to directly regulation of β3-intergin expression and then to produce the two different diseases. In addition, the expression of ESR1 is the major in the two ERs for contributes to proliferation. In this study, our data supported that overexpression of ESR2 suppress ESR1 and PGR in endometriosis, but the expression level of ESR2 was not enough for suppress ESR1 to severe proliferation. Furthermone, HOXA10 also plays a critical role for regulate the differentiation of EOC to endometrioid and mucinous subtypes. Our study was the first to establish the relationship between hormone control and the expression of HOXA10 in development of these two gynaecological diseases. These results may provide a new focus on the regulated information for hormone therapy, and provide HOXA10 as a potential biomarker for diagnosis the two diseases.